Glenmark Pharmaceuticals Ltd. - Research Center
532296 GLENMARK Group (A) BSE data
Add to watchlist
| Results |
Half yearly
|
| Statement | |
| More |
Half yearly results in brief
(Rs crore)
| Sep ' 24 | Sep ' 23 | Sep ' 22 | Mar ' 22 | Sep ' 21 | |
|---|---|---|---|---|---|
| Sales | 4,965.64 | 4,377.80 | 4,120.14 | 3,818.60 | 4,322.98 |
| Operating profit | 1,409.73 | 955.85 | 816.25 | 672.07 | 1,016.15 |
| Interest | 27.14 | 120.12 | 92.23 | 123.78 | 112.26 |
| Gross profit | 1,521.31 | 931.30 | 1,387.27 | 944.01 | 1,122.80 |
| EPS (Rs) | 37.17 | 20.34 | 32.45 | 26.73 | 44.08 |
Half yearly
results in details
| Sep ' 24 | Sep ' 23 | Sep ' 22 | Mar ' 22 | Sep ' 21 | |
|---|---|---|---|---|---|
| Other income | 138.73 | 95.58 | 663.25 | 395.73 | 218.90 |
| Stock adjustment | 64.81 | -17.01 | -61.11 | -15.81 | -0.33 |
| Raw material | 1,370.68 | 1,603.79 | 1,547.09 | 1,332.67 | 1,660.37 |
| Power and fuel | - | - | - | - | - |
| Employee expenses | 792.82 | 717.47 | 683.22 | 579.89 | 613.31 |
| Excise | - | - | - | - | - |
| Admin and selling expenses | - | - | - | - | - |
| Research and development expenses | - | - | - | - | - |
| Expenses capitalised | - | - | - | - | - |
| Other expenses | 1,327.61 | 1,117.71 | 1,134.69 | 1,249.78 | 1,033.48 |
| Provisions made | - | - | - | - | - |
| Depreciation | 107.94 | 98.60 | 91.20 | 82.57 | 77.13 |
| Taxation | 364.59 | 207.40 | 380.34 | 107.32 | 232.33 |
| Net profit / loss | 1,048.79 | 574.01 | 915.73 | 754.12 | 1,243.67 |
| Extra ordinary item | - | -51.30 | - | - | 430.33 |
| Prior year adjustments | - | - | - | - | - |
| Equity capital | 28.22 | 28.22 | 28.22 | 28.22 | 28.22 |
| Equity dividend rate | - | - | - | - | - |
| Agg.of non-prom. shares (Lacs) | - | - | - | - | - |
| Agg.of non promotoholding (%) | - | - | - | - | - |
| OPM (%) | 28.39 | 21.83 | 19.81 | 17.60 | 23.51 |
| GPM (%) | 29.80 | 20.82 | 29.00 | 22.40 | 24.72 |
| NPM (%) | 20.55 | 12.83 | 19.14 | 17.89 | 27.38 |
© 2025 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback
DISCLAIMER: All financials are on standalone basis